Search

everythinglearnresearchcommunity

for

Search:↓

The user has been using finasteride for 6 months and minoxidil for 12 months to address hair loss and recently started estradiol monotherapy for additional benefits. They are unsure if their hair is regrowing and are seeking advice on their progress.

Dermastamps are preferred over dermarollers for microneedling due to precision and reduced risk of scarring. Dermastamps allow for controlled, vertical needle entry, while dermarollers may cause more damage with sideways needle entry.

Bimatoprost (Latisse) shows promise in treating scalp alopecia. Users discuss its potential alongside Minoxidil, finasteride, and RU58841.

The user experienced significant hair regrowth using dutasteride daily for six months, then every other day, after stopping minoxidil. They did not use finasteride and reported no side effects.

Dutasteride studies for hair loss are often sponsored by GlaxoSmithKline, raising concerns about potential bias. Despite this, some users report positive results with dutasteride and oral minoxidil, while others remain skeptical of industry-funded research.

Oral hyaluronic acid is not beneficial for hair, as it gets broken down in the stomach and has no strong evidence supporting its effectiveness. The user is taking finasteride, dutasteride, and topical minoxidil for hair loss, but combining finasteride and dutasteride is considered redundant.

Eucapil (fluridil) may reduce hair shedding. It can be added to a regimen with finasteride and minoxidil.

The conversation is a satirical discussion about using grapefruit for hair regrowth, with suggestions ranging from injecting it to applying it topically or anally. Some users claim unusual benefits like emitting a green aura or jumping high.

The conclusion of this conversation is that the user experienced hair regrowth and increased overall hair thickness after using dutasteride and derma pen treatments for 5 years. They did not experience any side effects.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.